Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer

Clinical Cancer Research

Volumn 5, Issue 2, 1999, Pages 309-317

  Baker, Sharyn D ^a,b   Wirth, Mark ^c   Statkevich, Paul ^c   Reidenberg, Pascale ^c   Alton, Kevin ^c   Sartorius, Susan E ^b   Dugan, Margaret ^c   Cutler, David ^c   Batra, Vijay ^c   Grochow, Louise B ^b   Donehower, Ross C ^b   Rowinsky, Eric K ^b  

^a CTRC Institute for Drug Development   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; TEMOZOLOMIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HUMAN; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; SOLID TUMOR;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; AGED; AMINOIMIDAZOLE CARBOXAMIDE; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD PROTEINS; CARBON RADIOISOTOPES; DACARBAZINE; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS;

EID: 0033016056     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Newlands, E. S., Blackledge, G. R. P., Slack, J. A., Rustin, G. J. S., Smith, D. B., Stuart, N. S. A., Quarterman, C. P., Hoffman, R., Stevens, M. F. G., Brampton, M. H., and Gibson, A. C. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer, 65: 287-291, 1992.
2. O'Reilly, S. M., Newlands, E. S., Glaser, M. G., Brampton, M., Rice-Edwards, J. M., Illingworth, R. D., Richards, P. G., Kennard, C., Colquhoun, I. R., Lewis, P., and Stevens, M. F. G. Temozolornide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur. J. Cancer, 29A: 940-942, 1993.
3. Woll, P. J., Crowther, D., Johnson, P. W. M., Soukop, M., Harper, P. G., Harris, M., Brampton, M. H., and Newlands, E. S. Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. Br. J. Cancer, 72: 783-784, 1995.
4. Blechen, N. M., Newlands, E. S., Lee, S. M., Thatcher, N., Selby, P., Calvert, A. H., Rustin, G. J. S., Brampton, M., and Stevens, M. F. G. Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol., 13: 910-913, 1995.
5. Dhodapkar, M., Rubin, J., Reid, J. M., Burch, P. A., Pilot, H. C., Buckner, J. C., Ames, M. M., and Suman, V. J. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin. Cancer Res., 3: 1093-1100, 1997.
6. Levin, V., Yung, A., Prados, M., Poisson, M., Rosenfeld, S., Brada, M., Friedman, H., Albright, R., Olson, J., Bruner, J. Yue, N., and Dugan, M. Phase II study of Temodal (temozolomide) at first relapse in anaplastic astrocytoma (AA) patients. Proc. Am. Soc. Clin. Oncol., 16: 450a, 1997.
7. Stevens, M. F. G., Hickman, J. A., Langdon, S. P., Chubb, D., Vickers, L., Stone, R., Baig, G., Goddard, C., Gibson, N. W., Slack, J. A., Newton, C., Lunt, E., Fizames, C., and Lavelle, F. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo [5,1, d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M&B 39831], a novel drug with potential as an alternative to dacarbazine. Cancer Res., 47: 5846-5852, 1987.
8. Tsang, L. L. H., Quarterman, C. P., Gescher, A., and Slack, J. A. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother. Pharmacol., 27: 342-346, 1991.
9. Denny, B. J., Wheelhouse, R. T., Stevens, M. F. G., Tsang, L. L. H., and Slack, J. A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry, 33: 9045-9051, 1994.
10. 7 alkylation by three antitumor chloroethylating agents. Cancer Res., 46: 1943-1947, 1986.
11. 6-alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem. Pharmacol., 36: 457-462, 1987.
12. 6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas. Anticancer Drugs, 3: 401-405, 1992.
13. Kim, H. K., Lin, C., Parker, D., Veals, J., Lim, J., Likhari, P., Statkevich, P., Marco, A., and Nomeir, A. A. High-performance liquid chromatographic determination and stability of 5-(3-methyitriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. J. Chromatogr. B, 703: 225-233, 1997.
14. Shen, F., Decosterd, L. A., Gander, M., Leyvraz, S., Biollaz, J., and Lejeune, F. Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. J. Chromatogr. B, 667: 291-300, 1995.
15. Tsang, L. L. H., Farmer, P. B., Gescher, A., and Slack, J. A. Characterization of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother. Pharmacol., 26: 429-436, 1990.
16. Reid, J. M., Stevens, D. C., Rubin, J., and Ames, M. M. Pharmacokinetics of 3-Methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin. Cancer Res., 3: 2393-2398, 1997.
17. Breithaupt, H., Dammann, A., and Aigner, K. Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules. Cancer Chemother. Pharmacol., 9: 103-109, 1982.
18. Gibaldi, M., and Perrier, D. (eds.). Pharmacokinetics, Ed. 2, pp. 409-417. New York: Marcel Dekker, 1982.
19. Zimmerman, T. P., and Deeprose, R. D. Metabolism of 5-amino-1-β-D-ribofuranosylimidiazole-4-carboxamide and related five-membered heterocycles to 5′-triphosphates in human blood and L5178Y cells. Biochem. Pharmacol., 27: 709-716, 1978.
20. D'Argenio, D. Z., and Schumitzky, A. A program package for simulation and parameter estimation in pharmacokinetics. Computer Programs Biomed., 9: 115-1134, 1979.
21. Gibaldi, M. (ed.). Biopharmaceutics, and Clinical Pharmacokinetics, Ed. 4, pp. 220-221. Philadelphia: Lea and Febiger, 1991.
22. Flaks, J. G., Erwin, M. J., and Buchanan, J. M. Biosynthesis of the purines XVI. The synthesis of adenosine 5′-phosphate and 5-amino-4-imidazolecarboxamide ribotide by a nucleotide pyrophosphorylase. J. Biol. Chem., 228: 201-213, 1957.
23. Wyngaarden, J. B., Seegmiller, J. E., Laster, L., and Blair, A. E. Utilization of hypoxanthine, adenine and 4-amino-5-imidazolcarboxamide for uric acid synthesis in man. Metab. Clin. Exp., 8: 455-464, 1959.
24. Krenitsky, T. A., Neil, S. M., Elion, G. B., and Hitchings, G. H. Adenine phosphoribosyltransferase from monkey liver. Specificity and properties. J. Biol. Chem., 17: 4779-4784, 1969.
25. Thomas, C. B., Arnold, W. J., and Kelley, W. N. Human adenine phosphoribosyltransferase. Purification, subunit structure and substrate specificity. J. Biol. Chem., 248: 2529-2535, 1973.